Literature DB >> 23812966

Histone H1.0--a potential molecular marker with prognostic value for patients with malignant gliomas.

Nikolay Gabrovsky1, Milena Georgieva, Maria Laleva, Konstantin Uzunov, George Miloshev.   

Abstract

BACKGROUND: Histones are proteins closely associated with the DNA molecules and serve as a structural scaffold for the organization of chromatin. They play an important role in the regulation of gene expression by changing the level of DNA compaction. The special subtype of the linker histone family-H1 zero (H1.0) is generally expressed in non-dividing, terminally differentiated cells. The aim of our study is to investigate the correlation between the quantities of histone H1.0 in human gliomas, the histopathological grade and the overall survival. MATERIAL AND
METHOD: Twenty-nine (N = 29) patients with intraaxial lesions underwent a microsurgical tumor resection. Tumor samples were snap-frozen in liquid nitrogen immediately after resection. Following a specific protocol, linker histones were extracted from the tumor specimens and the quantities of histone H1.0 were assessed. All patients were followed up prospectively.
RESULTS: Of the 29 patients in our study (M:F = 17:12), five had a grade II astrocytoma, seven had a grade III, and 17 had a grade IV, according to the World Health Organization (WHO) classification. At the end of the study, three patients were still alive. The mean quantities of H1.0 were: 23.3 for grade II tumors, 13.9 for grade III and 11.3 for grade IV tumors. The statistical analysis demonstrated that the histological grade, age and Karnofsky performance status (KPS) remain among the most reliable predictive factors for the survival of patients with gliomas. Grade III-IV gliomas had significantly less histone H1.0 than grade II gliomas. Conformably, in a multivariate Cox regression analysis, H1.0 made a small but significant contribution (p < 0.05) to survival rates.
CONCLUSION: Our study confirmed that histone H1.0 is a potential biological marker with prognostic value for the survival of patients with gliomas. The quantities of histone H1.0 are correlated to the histopathological grade of the tumor. The more aggressive and malignant gliomas tend to have lower quantities of histone H1.0.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23812966     DOI: 10.1007/s00701-013-1802-1

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  5 in total

1.  Emerging role of linker histone variant H1x as a biomarker with prognostic value in astrocytic gliomas. A multivariate analysis including trimethylation of H3K9 and H4K20.

Authors:  Athanasia Sepsa; Georgia Levidou; Antonis Gargalionis; Christos Adamopoulos; Anastasia Spyropoulou; Georgia Dalagiorgou; Irene Thymara; Efstathios Boviatsis; Marios S Themistocleous; Kalliopi Petraki; George Vrettakos; Vassilis Samaras; Athanassios Zisakis; Efstratios Patsouris; Christina Piperi; Penelope Korkolopoulou
Journal:  PLoS One       Date:  2015-01-20       Impact factor: 3.240

2.  Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia.

Authors:  Alexey Zatula; Aida Dikic; Celine Mulder; Animesh Sharma; Cathrine B Vågbø; Mirta M L Sousa; Anders Waage; Geir Slupphaug
Journal:  Oncotarget       Date:  2017-03-21

Review 3.  H1.0 Linker Histone as an Epigenetic Regulator of Cell Proliferation and Differentiation.

Authors:  Carlo Maria Di Liegro; Gabriella Schiera; Italia Di Liegro
Journal:  Genes (Basel)       Date:  2018-06-20       Impact factor: 4.096

Review 4.  Histone Variants: Guardians of Genome Integrity.

Authors:  Juliette Ferrand; Beatrice Rondinelli; Sophie E Polo
Journal:  Cells       Date:  2020-11-05       Impact factor: 6.600

5.  Label-Free Mass Spectrometry-Based Quantification of Linker Histone H1 Variants in Clinical Samples.

Authors:  Roberta Noberini; Cristina Morales Torres; Evelyn Oliva Savoia; Stefania Brandini; Maria Giovanna Jodice; Giovanni Bertalot; Giuseppina Bonizzi; Maria Capra; Giuseppe Diaferia; Paola Scaffidi; Tiziana Bonaldi
Journal:  Int J Mol Sci       Date:  2020-10-04       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.